Elevated urinary excretion of the C5b.9 complex in membranous nephropathy. In experimental membranous nephropathy, antibody binding to glomerular epithelial cell membrane antigens results in complement activation and formation of complement C5b-9 membrane attack complexes in glomeruli. During active disease, the C5b-9 complexes are shed into the urine. To test the hypothesis that a similar mechanism might be operative in human membranous nephropathy, we measured urinary excretion of C5b-9 and CS in 146 proteinuric patients with biopsy-proven glomerular diseases or diabetes mellitus. Urinary excretion of C5b-9 relative to CS excretion was higher in 40 patients with membranous nephropathy than in 106 patients with proteinuria due to non-membranous glomerulonephritis when analyzed by covariance analysis (P < 0.0002). Urinary C5b-9 excretion was higher in membranous nephropathy than in membranoproliferative glomerulonephritis (N = 13, P < 0.05), minimal change-focal sclerosis (N = 33, P < 0.001), mesangial proliferative glomerulonephritis (N = 9, P < 0.02) and IgA nephropathy (N = 7, P < 0.025). Urinary C5b-9 excretion was also higher in patients with lupus nephritis (N = 18, P < 0.02) compared to those with non-membranous glomerulonephritis. The lupus patients with the highest excretion had clinical or pathological features of membranous nephropathy. Nine patients with membranous nephropathy and elevated urinary C5b-9 excretion had a shorter duration of disease (P < 0.05), lower serum creatinine levels (P < 0.05) and more proteinuria (P < 0.02) than the 31 membranous nephropathy patients with normal values. The finding of increased urinary CSb-9 excretion in a subset of patients with idiopathic or lupus membranous nephropathy suggests an autoimmune basis for glomerular disease in these patients, and may indicate that these patients have ongoing immune deposit formation.
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Membranous nephropathy is the most common cause of idiopathic nephrotic syndrome in adults and is characterized by subepithelial deposits of immunoglobulin, C3 and C5b-9 in a finely granular pattern [1] . The antigen to which these deposited antibodies is directed has not been identified in humans. In rats, an identical lesion is induced by deposition of antibody directed against antigen(s) expressed on the membrane of the glomerular epithelial cell (Heymann nephritis) [2] . Proteinuria in Heymann © 1991 by the International Society of Nephrology nephritis is mediated by epithelial cell membrane insertion of the CSb-9 membrane attack complex [3, 4] which is endocytosed, transported intracellularly and then exocytosed in the urinary space [5] . Urinary C5b-9 excretion occurs only when subepithelial deposits result from antibody binding to the epithelial cell [6] , and urinary C5b-9 excretion closely parallels ongoing glomerular immune deposit formation and therefore disease activity [6, 7] .
We reasoned that if a similar autoimmune mechanism mediates membranous nephropathy in humans, a subset of patients with active disease should exhibit increased urinary C5b-9 excretion that might serve as a non-invasive measure of disease activity. Our findings demonstrate the urinary C5b-9 excretion significantly exceeds expected values in patients with membranous nephropathy compared to patients 'with several other proteinuric glomerular diseases. Moreover, patients with elevated urinary C5b-9 excretion have more proteinuria, a shorter duration of disease and better renal function than patients with normal urinary C5b-9 values, suggesting that increased urinary C5b-9 excretion may be a marker of disease activity.
Methods

Urine sample collection
We analyzed random urine specimens obtained for routine testing from 38 normal subjects and 146 patients (54 woman, 92 men, mean age 38.4 years; range 3 to 76 years) with proteinuria due to a variety of glomerular diseases. Proteinuria was defined as a ratio of protein to creatinine concentrations exceeding 0.022 mg/zmol creatinine (0.2 mg/mg). With the exception of those patients with diabetes mellitus and nephropathy and two patients with lupus nephritis, all patients had diagnoses of glomerular disease documented by renal biopsy. Disease duration at the time of study in patients with membranous nephropathy was defined as the time in months from the onset of documented proteinuria or, if this was not known, from the time of renal biopsy to the time of urine sample collection. All other clinical parameters were measured at the time of urine sample collection. Freshly voided urine was mixed 9:1 vol/vol with Tris-HC1 pH 8.6 buffer containing 0.1% NaN3 (wt/vol), 100 mri bezamidine, 100 mr.t epsilon-amino-caproic acid (EACA, Sigma Chemical Co., St. Louis, Missouri, USA), 200 mr'i EDTA, aprotinin (100 kallikrein inhibitor U/mi) and 0.5% Tween 20 (vol/vol), and stored at 4°C. C5b-9 in proteinuric urine was stable under these conditions for over one year. Urine protein was determined by precipitation with sulfosalicylic acid and creatinine by the picric acid method (Worthington Diagnostics, Freehold, New York, USA).
Preparation and characterization of antibodies to human
C5a, C5b, C6, C9 and C5b-9 neoantigen Immunoglobulin (IgG) fractions of monospecific goat antisera against the human complement components C6 and C9 (Genzyme, Boston, Massachusetts) were biotinylated using biotin-X-NHS (Calbiochem, La Jolla, California, USA) as described elsewhere [6, 8] .
For ELISAs, monoclonal antibodies to CSa, to the CS beta-chain detecting the C5b moiety of CS, and to C5b-9 neoantigen were prepared using standard protocols [81. The monoclonal antibody to human C5a (F241l) was raised by immunization with purified C5a and characterized as described previously [9] . A monoclonal antibody (N20/9) to CS was raised by immunization with purified C5 and biotinylated as described elsewhere [8] [9] [10] . By SDS-PAGE and immunoblotting [11, 12] , this antibody reacted with purified intact human CS (Fig. 1 , lane c) and with the beta-chain of C5 after reduction with DTT (Fig.  1, lane d) , and was therefore specific for the C5b-moiety of C5. The monoclonal antibody (W13/15) reacted with C9 obtained from human complement lysed rabbit erythrocytes prepared as described by Biesecker et al 113] (Fig. 2, lane b) , but not with native C9 in EDTA-plasma (Fig. 2 , lane a), and was therefore reactive with a CSb-9 neoantigen.
Monoclonal antibody binding to plasma proteins (Figs. 1 and 2) separated by SDS-PAGE [11] was studied by immunoblotting [12] using biotinylanted sheep antibody to mouse IgG (Amersham, Arlington Heights, Illinois, USA), streptavidin-peroxidase, and the peroxidase substrate 4-chloro-1-naphtole [8] .
Measurement of urinary excretion of C5b-9
The C5b-9 ELISA was performed on microtitration plates (Dynatech, Chantilly, Virginia, USA; NUNC, Roskilde, Denmark) coated with the monoclonal antibody (W131l5) to human C9 neoantigen as capturing antibody. Nonspecific binding was blocked by incubation of the plates with 0.2% casein (Sigma) and by pre-incubating urine samples with heat-aggregated (63°C, 6 hrs) goat IgG (1.6 mg/mI urine) for 30 minutes. For C5b-9 detection wells were incubated with biotinylated polyclonal anti-human C6 antibody, 2 gig/well, washed and then incubated with streptavidin-peroxidase (Amersham). Color was developed with 2.2'-azinodi-(3-ethyl-benzthiazolinesulfonate) (ABTS) (Boehringer Mannheim) and 2.5 msi H202 and read at 405 nm using a microplate reader (Dynatech MR 560). The Measurement of urinary excretion of C5 Excretion of CS was measured in all urine samples by ELISA using the anti-C5a monoclonal antibody (F24/l) as a capturing antibody and biotinylated anti-C5b antibody (N20/9) as the detecting antibody. The ELISA to C5 was standardized using EDTA-plasma calibrated with purified C5 [101 and had a detection limit of 60 ng/ml [141.
Data analysis
Concentrations of C5b-9, C5, total protein and creatinine were measured in each urine sample. To include samples with no detectable C5 or C5b-9, a constant of 0.03 g/ml was added to all C5 and C5b-9 values. To correct for differences in urine concentration, values of C5b-9 and CS were expressed per tmol of creatinine and the skewness of the data was reduced by conversion to logarithms. Comparisons of the urinary C5b-9/ creatinine and C5/creatinine ratios between groups were done by Wilcoxon rank sum test [15].
C5b-9 was found in most proteinuric urines, suggesting some spontaneous formation of C5b-9 from native complement components in post-glomerular proteinuric urine. To correct for this, measured C5b-9 excretion was compared to expected C5b-9 excretion determined from a regression line that related C5b-9 excretion to CS excretion. The rationale for relating C5b-9 excretion to C5 rather than total protein is presented below in results. To determine if there was a significant difference between measured and expected values for urinary C5b-9 excretion in the group of patients with membranous nephropathy compared to other groups, co-variance analysis of urinary C5b-9/creatinine was performed using urinary C5/creatinine as the covariate and employing the SSPS statistical package (SSPS, V2.0, Chicago, Illinois, USA) [161. Differences were considered significant if analysis of variance yielded a P value of < 0.05 [16) .
To determine if urinary C5b-9 excretion in individual patients was elevated above expected values based on CS excretion, we used a standard formula to plot a regression line between log transformed values of urinary C5b-9/creatinine and C5/creati-nine using data from all patients except those with membranous nephropathy or lupus nephritis, the two groups with elevated urinary C5b-9 excretion. We then measured the distance of each individual value from the regression line in standard deviations of Student's t-distribution (standardized residuals) [161. Individual values were regarded as elevated if they equaled or exceeded 1.65, a value indicating a 95% probability that the result was elevated above the mean of the regression line using a single tailed test [16] .
We used Student's t-tests to compare proteinuria, serum creatinine values and time from onset of disease between patients with membranous nephropathy with elevated and those with "normal" urinary C5b-9 excretion. Tests to compare serum creatinine and time from onset of disease were performed on the logarithms of the data to account for variance in-homogeneity. With the exception indicated above, two-tailed tests were used in all statistical comparisons. P values < 0.05 were considered significant.
Results
Urine c5b-9, C5 and protein excretion in patients with glomerular disease The urinary protein/creatinine, total C5b-9/creatinine and C5/creatinine ratios for each group are shown in Table 1 . No C5b-9 was detected in the urine samples from 38 normal subjects. Urinary C5b-9 was detectable in most patients who had a urinary protein/creatinine ratio greater than 0.34 mg/mol (3.0 mg protein/mg creatinine). The mean urinary C5b-9 concentration was significantly higher (P < 0.004) in patients with membranous riephropathy than in patients with non-membranous nephropathy. This value was also higher (P < 0.02) in patients with diabetic nephropathy compared to non-diabetic patients.
The presence of C5b-9 in urine from most patients with proteinuria, and the weak relationship between urine C5b-9 excretion and urinary protein excretion (r = 0.29, P < 0.001), suggested that some spontaneous generation of C5b-9 may occur from native complement components in urine after filtration and before collection in protease inhibitors. If so, differences in urinary C5b-9 excretion could simply reflect differences in total protein excretion between disease groups. To account for this possibility, the urinary C5b-9 values were related to urinary C5 excretion. Urinary C5 was selected rather than total urinary protein or the urinary content of some other plasma protein for several reasons. Of all components of the C5b-9 complex, C5 has the highest molecular weight, and therefore, it should have the lowest fractional clearance. As proteolytic cleavage of C5 also initiates the formation the C5b-9 complex it should represent the limiting factor for generation of C5b-9 in urine. The correlation between the urinary C5b-9 and C5 excretion (r = 0.80, P < 0.001) also was stronger than between urinary C5b-9 and urinary protein excretion, Using co-variance analysis, the log of urinary C5b-9/creatinine in membranous nephropathy was therefore compared with the non-membranous group as a whole and with individual disease groups, with log C5/creatinine as the covariate. The membranous group exhibited significantly elevated urinary C5-9 excretion compared to all non-membranous patients (P < 0.002) and also compared to individual groups of patients with membranoproliferative glomerulonephritis (P < 0.05), minimal change! focal sclerosis (P < 0.001), mesangial proliferative glomerulonephritis (P < 0.02) and IgA nephropathy (P < 0.025). Urinary C5b-9 excretion was also higher than expected based on C5 excretion in patients with membranous nephropathy compared to patients with diabetes, rapidly progressive glomerulonephritis and a group of miscellaneous glomerular diseases, but these differences did not reach statistical significance.
Similar co-variance analysis revealed that urinary C5b-9
excretion was also elevated in the group of patients with lupus nephritis compared to non-membranous nephrotic patients (P < 0.02), but not in other disease groups. When values in individual patients were analyzed for their 3) indicating a 95% probability that urinary C5b-9 excretion was elevated above expected values. Four patients with lupus nephritis also had elevated values by this criteria. Two of these patients had biopsy-proven membranous glomerular lesions and two had severe steroid-resident nephrotic syndrome with normal renal function and were suspected on a clinical basis to have membranous lesions [171. One patient with a membranoproliferative glomerulonephritis and subepithelial immune deposits by electron microscopy, and one patient with a mesangial capillary lesion in the miscellaneous group also had elevated individual urinary C5b-9 excretions. All other patients tested had values within 1.65 standard deviations of the mean predicted amount of C5b-9.
Clinical characteristics Table 2 shows the clinical characteristics of the nine patients with membranous nephropathy who had elevated C5b-9 excretion compared to the 31 membranous patients with normal values. The mean duration of disease at the time of study in the patients with elevated C5b-9 excretion was shorter than in the other patients (1.0 years, range 0.1 to five years; vs. 3.8 years, range 0.2 to 16 years, P < 0.05). Patients with elevated values also had more proteinuria (protein to creatinine ratio 1.48 0.72 mg'mol vs. 0.82 0.70 mg!mol, P < 0.02) and better renal function (serum creatinine 99.2 20.2 /Lmol/liter vs. 171 108.6 fLmol/liter, P < 0.05).
Discussion
These results demonstrate that proteinuric patients excrete detectable amounts of C5b-9 complexes regardless of their underlying glomerular disease, and in diseases where glomerular complement deposits are not routinely detected by immunofluorescence. The size of the C5b-9 complex (1000 kD) suggests that its filtration should be negligible, a contention supported by experimental studies [6, 18] . Thus, in humans some assembly of C5b-9 from filtered native components must occur in the urine. Because CS (200 kD) is the largest component of the precursors of the C5b-9 complex, the urinary C5 concentration should be the factor limiting the generation of C5b-9 in urine. We therefore related the urinary C5b-9 values to the urinary CS values to identify C5b-9 excretion above that . 1.0 0.1 0 which might occur spontaneously due to filtered native complement components. Using covariance analysis we found a significant increase of urinary C5b-9 excretion in patients with membranous nephropathy compared to all non-membranous patients with nephrotic syndrome. Urinary C5b-9 excretion was also elevated in patients with membranous nephropathy compared to groups of patients with other common causes of proteinuria including membranoproliferative glomerulonephritis, minimal change/focal sclerosis, mesangial proliferative gbmerulonephritis and IgA nephropathy. Although the values for urinary C5b-9 excretion in membranous nephropathy were also higher than those in patients with diabetes, rapidly progressive glomerulonephritis and a miscellaneous group of glomerular diseases, these differences did not reach statistical significance.
The finding of increased urinary C5b-9 excretion was not entirely specific for membranous nephropathy nor were the values increased in all patients with membranous nephropathy. Among the 106 patients with non-membranous nephropathy studied, six had elevated values. Four of these patients had lupus nephritis, and two had biopsy-proven membranous gbmerular lesions. The other two lupus patients had developed severe steroid-resistant nephrotic syndrome several years after biopsies had revealed mild-diffuse proliferative glomerulonephritis. They were therefore suspected clinically to have membranous lesions [17] . Five other patients with known membranous lupus nephritis and nine patients with other forms of lupus nephritis of varying severity did not have elevated values, although glomerular C5b-9 deposits and elevated circulating C5b-9 levels are commonly found in such patients [19, 201 . This observation suggests that the mechanism by which subepithelial deposits are formed in some patients with membranous lupus nephritis may be similar to that in some patients with idiopathic membranous nephropathy.
This finding of elevated urinary C5b-9 excretion in some patients with membranous nephropathy supports the hypothesis that the pathogenesis of this disease may be similar to that defined in the Heymann nephritis models in rats [I]. In Heymann nephritis, subepithelial deposits of IgG and complement result from antibody binding to an antigen(s) of the glomerular epithelial cell membrane, and C5b-9 assembly and membrane insertion is required for proteinuria to develop [reviewed in 1].
Studies of a variety of models of immune and non-immune glomerular disease have shown that increased urinary C5b-9 excretion occurs only in membranous nephropathy induced by antibodies to glomerular epithelial cell antigens and it does not occur when glomerular immune complex or C5b-9 deposits result from other mechanisms [6] . The mechanism of urinary C5b-9 excretion appears to involve endocytosis of membraneinserted C5b-9 complexes by glomerular epithelial cells followed by transcellular transport and exocytosis into the urinary space [5] . In rats, urinary C5b-9 excretion ceases immediately following cessation of antibody deposition, despite persistence of proteinuria, and thus serves as a sensitive index of disease activity [6, 7] . Thus one implication of our findings is that the pathogenesis of membranous nephropathy in humans, at least in a subset of patients, involves an autoimmune mechanism. Our data further suggest that a similar mechanism may be operative in some patients with lupus membranous nephropathy.
Our findings do not exclude the possibility that most, or even all, patients with idiopathic membranous nephropathy have a similar mechanism operative, but that antibody deposition was not ongoing at the time of study in many patients. Patients were studied randomly and often not during early or active disease.
The observations that patients with elevated urinary C5b-9
excretion had significantly more proteinuria as well as a shorter duration of disease when studied are consistent with the possibility that urinary C5b-9 excretion may provide a non-invasive index of disease activity in membranous nephropathy in humans as it does in rats. This finding may be of clinical utility in human membranous nephropathy. In membranous nephropathy the pathogenic antibody has not been identified and therefore cannot be measured, proteinuria is variable and poorly responsive to therapy initially, and therapy is potentially toxic and probably indicated only in certain patients expected to have progressive disease [7, [21] [22] [23] . Further studies will be required to establish the relationship between urinary C5b-9 excretion and prognosis or response to therapy.
